Ernst is a business-orientated scientist with broad scientific training in oncology, infectious diseases and chemistry with a strong interest in valorization of science. Ernst holds a PhD in molecular cancer genetics from the Netherlands Cancer Institute (NKI-AvL). He then continued his career as business developer at TNO, where he gained experience in marketing, business consultancy, international business development and venturing. He had a major role in spinning-out technologies from the Earth, Environmental and Life Sciences department. He currently works as associate at Aglaia BioMedical Ventures, a venture capital firm with a focus in oncology diagnostics and therapeutics. Aglaia identifies groundbreaking opportunities in cancer research and, in close partnerships with inventors and entrepreneurs, takes these opportunities to the next phase of technical and commercial development. At Aglaia, Ernst is responsible for analysis of investment proposals as well scouting for new investment opportunities.
Results of Phase II Combination Trial of ISA101 and Nivolumab to be Presented at ESMO 2017
Macrophage Pharma Extends Series A Round to Include New Investor Merck Ventures